Evernow Pricing Analysis & Total Cost

How Evernow's Pricing Model Works

Evernow operates as a cash-pay telehealth platform focused exclusively on menopause and perimenopause. The structure is straightforward: a one-time consultation fee, a recurring monthly membership, and medication costs billed separately. No insurance is accepted.

This model mirrors the broader trend in direct-to-consumer hormone therapy platforms that bypass traditional insurance billing. The 2022 Menopause Society position statement noted that approximately 75% of symptomatic menopausal women remain untreated, partly due to access barriers in conventional care [1]. Platforms like Evernow attempt to address this gap, but the cash-pay structure means patients absorb the full cost without copay assistance.

The monthly membership ($49) covers unlimited messaging with a provider, follow-up visits, and prescription adjustments. Medications ship directly to the patient, with pricing that varies by formulation. Estradiol patches (generic) typically run $30 to $50/month through Evernow's pharmacy partners, while branded formulations or compounded options can push past $90/month. Oral micronized progesterone (generic Prometrium equivalent) adds another $20 to $40/month for those on combined therapy.

One cost often overlooked: lab work. Evernow does not include baseline or follow-up labs in its pricing. Patients need to arrange their own estradiol, FSH, thyroid, and lipid panels through a primary care provider or third-party lab service, adding $100 to $300 per testing round depending on the panel.

First-Year Total Cost Breakdown

The first year with Evernow represents the highest annual expenditure because of the one-time consultation fee and any initial lab work needed before starting HRT.

Here is a realistic first-year scenario for a patient starting combined estradiol/progesterone therapy:

• Initial consultation: $149
• Monthly membership (12 months): $588
• Estradiol patch, generic (12 months at ~$40/month): $480
• Oral micronized progesterone (12 months at ~$30/month): $360
• Lab work (2 rounds, estimated): $250

That totals approximately $1,827 for year one. Year two drops to roughly $1,428 by eliminating the consultation fee and reducing lab frequency.

These figures align with broader estimates of cash-pay HRT costs. A 2023 analysis in Menopause found that out-of-pocket hormone therapy costs for uninsured women averaged $1,200 to $2,400 annually depending on formulation complexity [2]. Evernow falls in the lower-middle portion of that range for standard regimens, though patients requiring compounded bioidentical formulations or multiple medications may exceed it.

Is Evernow Legitimate? Clinical Credibility Assessment

Evernow employs board-certified physicians and nurse practitioners specializing in menopause care. The platform's prescribing practices appear to follow the 2022 Hormone Therapy Position Statement from The Menopause Society (formerly NAMS), which recommends initiating HRT in symptomatic women under 60 or within 10 years of menopause onset [1].

The platform prescribes FDA-approved hormone therapy products: transdermal estradiol (Climara, Vivelle-Dot generics), oral micronized progesterone, and in some cases vaginal estrogen for genitourinary syndrome of menopause. This is standard, evidence-based practice. The WHI follow-up data published in JAMA (2017) confirmed that for women aged 50 to 59, conjugated equine estrogen plus medroxyprogesterone acetate showed no increase in all-cause mortality over 18 years of cumulative follow-up [3].

Where legitimacy questions arise is not in prescribing standards but in the limitations of a text-based care model. The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy emphasizes individualized risk assessment including breast cancer history, cardiovascular risk factors, and thrombotic risk [4]. Whether an asynchronous telehealth visit can adequately capture this nuance depends heavily on the intake questionnaire design and provider thoroughness.

Dr. Stephanie Faubion, medical director of The Menopause Society, has stated: "The biggest barrier to menopause care isn't the science. It's access to clinicians who actually understand the evidence." Evernow attempts to solve the access problem, and its clinical protocols appear sound based on publicly available prescribing information. The question for consumers is whether the premium over insurance-covered alternatives is justified by convenience and specialization.

Evernow vs. Competitors: Price Comparison

The direct-to-consumer menopause telehealth market has expanded rapidly. Here is how Evernow stacks up against its primary competitors on cost.

Midi Health accepts commercial insurance and Medicare for women 40+. For insured patients, out-of-pocket costs may be limited to copays ($20 to $75 per visit) plus medication copays. For those paying cash, Midi's rates are comparable to Evernow's consultation pricing but potentially cheaper long-term due to insurance billing for prescriptions. A 2024 study in the Journal of Women's Health found that insurance coverage reduced annual HRT costs by 60 to 80% compared to cash-pay models [5].

Alloy uses a product-bundled model, selling specific HRT formulations at set prices. Estradiol patches start at approximately $85 per quarter ($28/month), and combination kits run $120 to $150 per quarter. There is no separate membership fee, which simplifies the math. Annual cost for a basic estradiol patch regimen: approximately $340 for medication alone, plus $99 per provider consultation.

Winona charges a monthly membership ($99/month for some plans) that bundles provider access and certain medications. Total annual costs range from $1,188 to $1,800+, putting it at or above Evernow for comparable regimens.

Traditional in-network provider with commercial insurance: A gynecologist or menopause specialist visit ($30 to $50 copay), plus generic estradiol patch ($10 to $25/month with insurance), plus generic progesterone ($5 to $15/month with insurance). Annual total: $300 to $600 for insured patients. This remains the cheapest option for those with adequate coverage and access to a knowledgeable provider.

The value proposition for Evernow becomes clearest for women without menopause-trained providers in their area, those with high-deductible health plans, or those who prioritize the convenience of a menopause-specialized platform over navigating general gynecology appointments.

What Evernow Prescribes

Evernow's formulary centers on FDA-approved hormone therapy and select non-hormonal alternatives for vasomotor symptoms. The platform does not prescribe testosterone for women (off-label in the U.S.) or compounded bioidentical hormone preparations.

Standard prescriptions include:

• Transdermal estradiol (0.025 mg to 0.1 mg patches, changed once or twice weekly): The KEEPS trial demonstrated that transdermal estradiol 50 mcg/day improved vasomotor symptoms by 80 to 90% versus placebo over 4 years [6].
• Oral micronized progesterone (100 mg to 200 mg nightly): Required for endometrial protection in women with a uterus. The PEPI trial established that micronized progesterone provides endometrial safety comparable to medroxyprogesterone acetate while producing a more favorable lipid profile [7].
• Vaginal estrogen (estradiol cream or tablets): For genitourinary syndrome of menopause. The Cochrane review of 30 trials (N=6,235) found that low-dose vaginal estrogen significantly improved dryness, dyspareunia, and urinary symptoms versus placebo [8].
• Non-hormonal options: For patients who cannot or prefer not to use HRT, Evernow may prescribe paroxetine 7.5 mg (Brisdelle, the only FDA-approved non-hormonal for hot flashes) or off-label low-dose venlafaxine/gabapentin.

The prescribing scope is conservative and evidence-based. This is both a strength (patient safety) and a limitation (patients seeking testosterone, DHEA, or custom compounding will need to look elsewhere).

The Perimenopause Question: Does Evernow Cover Early Symptoms?

Yes. Evernow explicitly markets to perimenopausal women, not only those who are postmenopausal. This matters because perimenopause, which can begin 4 to 8 years before the final menstrual period, often presents with irregular cycles, sleep disruption, mood volatility, and vasomotor symptoms that benefit from treatment [9].

The SWAN study (Study of Women's Health Across the Nation, N=3,302) documented that vasomotor symptoms peak in the late perimenopausal transition, with a median total duration of 7.4 years [10]. Starting treatment during perimenopause rather than waiting until postmenopause may provide longer total symptom relief.

For perimenopausal patients, Evernow typically prescribes low-dose transdermal estradiol with cyclic progesterone (to regulate bleeding patterns and protect the endometrium). This approach follows The Menopause Society guidance, which states that hormone therapy can be initiated during the menopausal transition when symptoms warrant treatment [1].

The cost structure is identical for perimenopausal and postmenopausal patients. There is no separate "perimenopause plan." The main difference is clinical: perimenopausal patients may require more frequent dose adjustments in the first 6 to 12 months as their endogenous hormone production continues to fluctuate, potentially making the unlimited messaging benefit of the monthly membership more valuable during this phase.

Hidden Costs and Limitations

Several costs are not immediately apparent in Evernow's marketing materials.

Lab work gaps. Baseline labs (estradiol, FSH, TSH, CBC, lipid panel, liver function) are clinically recommended before starting HRT, per Endocrine Society guidelines [4]. Evernow providers may order these, but the patient pays out of pocket through Quest, Labcorp, or a third-party service. Expect $150 to $300 per round.

Medication price variability. Evernow's pharmacy partner pricing is not always the cheapest available. Generic estradiol patches through GoodRx or Cost Plus Drugs may run $15 to $25/month versus $35 to $50 through Evernow's fulfillment. Patients who bring their own pharmacy (if permitted) could save $120 to $300 annually.

No coverage for related conditions. Evernow treats menopause symptoms specifically. Patients who develop thyroid dysfunction, osteoporosis requiring bisphosphonates, or cardiovascular concerns during the menopausal transition will still need a separate primary care or specialist relationship. Bone density monitoring (DEXA scanning), recommended by the USPSTF for all women 65+ and postmenopausal women under 65 with risk factors [11], is not coordinated through Evernow.

Cancellation and switching costs. Patients who start medications through Evernow's pharmacy and then switch to an insurance-covered provider may face gaps in refills during the transition. Abrupt discontinuation of HRT, particularly estrogen, can trigger rebound vasomotor symptoms.

Who Gets the Most Value from Evernow

The cost-benefit calculation favors specific patient profiles.

Good fit: Women with high-deductible insurance plans (where medication costs count toward deductible anyway), those in provider deserts without menopause-trained clinicians within reasonable distance, patients who have been dismissed or undertreated by general practitioners unfamiliar with current HRT evidence, and those who value the convenience of a specialized platform with rapid response times.

Poor fit: Women with strong commercial insurance and in-network access to a menopause-certified provider (where total annual costs would be 50 to 75% lower), patients who need testosterone or compounded formulations, those requiring comprehensive care coordination across multiple conditions, and price-sensitive patients who are comfortable navigating pharmacy discount programs independently.

A 2021 cross-sectional analysis in Maturitas found that women with menopause-specific telehealth access reported higher treatment satisfaction scores (OR 2.3 to 95% CI 1.4 to 3.8) compared to those receiving menopause care through general practice [12]. Whether that satisfaction premium is worth $500 to $1,000 annually above insured care is an individual calculus.

Long-Term Cost Trajectory

HRT is not a short-term intervention for most women. The Menopause Society's 2022 position statement notes that there is no mandatory maximum duration for HRT and that continuation should be based on individualized benefit-risk assessment [1]. Many women use hormone therapy for 5 to 10+ years.

Over a 5-year period with Evernow, assuming no price increases:

• Year 1: ~$1,827 (with labs and consultation)
• Years 2 through 5: ~$1,428/year
• 5-year total: ~$7,539

The same regimen through an in-network provider with commercial insurance over 5 years: approximately $1,500 to $3,000 total.

The gap is substantial. Patients choosing Evernow are paying a premium of roughly $4,500 to $6,000 over five years for specialization, convenience, and rapid access. Whether that premium delivers proportional clinical value depends on individual circumstances, local provider availability, and insurance status.

For patients currently spending $200+ per month on unmonitored supplements, "bioidentical" compounding pharmacies without evidence-based oversight, or repeated unsuccessful primary care visits, Evernow may actually represent cost savings by consolidating care under a specialized provider who prescribes FDA-approved therapies with documented efficacy.